Beone Medicines revenue and financials
Secondary listing. The primary listing is BeOne Medicines · NASDAQ (USD)
$217.00Change from previous close: −1.63%Absolute change: −$3.60
In the fiscal year ended December 2025, Beone Medicines reported revenue of $5.34B (+40.23% year over year). Net income was $286.93M, a net margin of 5.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +40.23%
- 2025 vs 2024
- Net margin
- 5.4%
- 2024: -16.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 463 | 201 | 417 | 403 | 264 | — |
| Depreciation and amortization | 40.5 | 41.1 | 36.0 | 37.3 | 35.6 | — |
| Capital expenditure | -48.0 | -40.8 | -37.5 | -48.8 | -63.8 | — |
| Investing cash flow | -49.4 | -45.5 | -38.3 | -49.3 | -66.6 | — |
| Financing cash flow | -6.1 | 68.6 | 96.9 | 961 | 35.0 | — |
| Debt issued | 0.0 | 58.2 | 863 | 0.0 | 142 | — |
| Debt repaid | -17.1 | -7.6 | -784 | -4.3 | -115 | — |
| Effect of exchange rates | 19.8 | 19.3 | 23.2 | 9.9 | 23.5 | — |
| Net change in cash | 407 | 224 | 476 | 1,315 | 232 | — |
| Free cash flow | 415 | 161 | 380 | 354 | 200 | — |